On October 16, 2025 Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class therapies targeting escape mutations in hematologic malignancies and solid tumors, reported the presentation of preclinical data for its novel, brain-permeable CDK2 inhibitor at AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper). The compound demonstrates high selectivity for CDK2 over other cyclin-dependent kinases (CDKs), excellent safety and tolerability, and a broad therapeutic window in models of multiple cyclin-E1 (CCNE1)–CDK2–dependent neoplasms that exhibit poor response to current standard-of-care treatments, including approved CDK4/6 and investigational CDK2 inhibitors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Eilean plans to present the drug candidate data at AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) and to advance this highly selective CDK2 inhibitor into a First-in-Human clinical study in Q4 2025.
"Targeting CCNE1/CDK2-driven cancers remains an urgent unmet medical need," said Nikolay Savchuk, PhD, Chief Operating Officer at Eilean Therapeutics. "Our data demonstrate that this compound achieves an optimal balance of potency, selectivity, and brain permeability, supporting its potential to benefit patients with aggressive, therapy-resistant solid tumors."
(Press release, Eilean Therapeutics, OCT 16, 2025, View Source [SID1234656715])